Anges has concluded a contract regarding the expanded newborn screening tests at Nagano Prefectural Children's Hospital and Nagano Prefecture.

On the 24th, Anges <4563> announced that it had signed a contract for expanded newborn screening tests with Nagano Prefectural Children's Hospital and Anges Clinical Research Laboratory (ACRL). ACRL, which is a health inspection laboratory primarily aimed at rare genetic disease testing, will carry out paid screening for early diagnosis and early treatment of 10 rare genetic diseases, which is highly effective, as commissioned by the Children's Hospital.

Fisco JapanDec 25 16:45

DWTI, Anges and others [Emerging Markets press release]

Acquired and canceled all of the remaining 4th subscription rights (with exercise price adjustment clause) of ＜1447＞SAAFHHD. Terminated capital and business alliance with ＜3224＞G Oyster Hanwa Trading Company. Completed acquisition of treasury stock for ＜3646＞Ekitan. Entered into a contract regarding expanded newborn screening tests in Nagano Prefecture with Nagano Children's Hospital for ＜4563＞Anges. Patent examination for glaucoma treatment agent "H-1337" (South Korea) for ＜4576＞DWTI. Oncolytic virus from ＜4588＞Oncolis Bio.

Fisco JapanDec 25 06:30

Stocks that moved the day before part 2: Eyes, Eurasia Travel Agency, Japan Oxygen HD, etc.

Stock name <code> 5-day closing price ⇒ change from previous day China Electrical Utilities <9504> 902.0 -34.7 Major electrical utilities stocks are generally in a sell-dominant trend. Japan Oxygen HD <4091> 4332 -135 morgan stanley MUFG Securities has lowered its target stock price. Rakuten Bank <5838> 4110 -126 Expectations for postponing the Bank of Japan's interest rate hike in December are strengthening. Kasumigaseki Capital <3498> 12390 -400 Approaching the 25-day moving average, profit-taking could be dominant. Tohoku Electrical Utilities <9506>

Fisco JapanDec 6 06:32

AnGes---Collaboratively developed Tie2 receptor agonist (AV-001) enters the final stage of Phase 2 clinical trials in the previous period

Anges <4563> has announced that in the early phase 2 clinical trial of the Tie2 receptor agonist (AV-001) being jointly developed with Vasomune Therapeutics, a Canadian biopharmaceutical company, the evaluation by an independent data safety monitoring committee in the USA concluded that there are no safety issues, and has recommended transitioning to the final cohort (highest dose). The Tie2 receptor agonist is

Fisco JapanDec 5 14:21

Active and newly listed stocks during the morning session.

*Osaka Soda <4046> 1639 +220 The movement of reassessment progresses after receiving the briefing the previous day. *KeePer Engineering <6036> 4605 +410 Existing stores in November show positive recovery for the first time in 2 months. *Celestica <3696> 2734 +194 Due to events such as bitcoin reaching $0.1 million. *Kawasaki Heavy Industries <7012> 6726 +424 Continues to attract attention as a core player in defense-related sector. *Kumagai Gumi <1861> 4070 +250 Nomura Securities has upgraded the investment rating.

Fisco JapanDec 5 12:35

Steady, supported by high US stocks [Emerging Markets Individual Stock Strategy]

[Emerging Markets Individual Stock Global Strategy] Today's emerging markets are expected to show a robust performance. Yesterday, on the 4th, in the U.S. stock market, the Dow Inc. rose by 308.51 points (+0.69%) to 45,014.04, marking a rebound after three days. The strong job growth confirmed by the private sector's November ADP employment statistics and the decline in long-term interest rates supported stock prices. Additionally, toward the end, Federal Reserve Chairman Powell expressed an optimistic view on the economy in an interview, and the Federal Reserve announced.

Fisco JapanDec 5 07:20